AstraZeneca Pharma rises 4% on getting CDSCO nod to import cancer treatment drug

AstraZeneca Pharma stock has risen 57 percent in the last one year, outperforming benchmark Nifty 50 which has risen 30 percent during the same period.

Read More

Top 100 Best Sellers

​ AstraZeneca Pharma stock has risen 57 percent in the last one year, outperforming benchmark Nifty 50 which has risen 30 percent during the same period. AstraZeneca Pharma stock has risen 57 percent in the last one year, outperforming benchmark Nifty 50 which has risen 30 percent during the same period.  Moneycontrol Latest News Read More